請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/72696
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 張永祺 | |
dc.contributor.author | Pei-Yun Lin | en |
dc.contributor.author | 林佩昀 | zh_TW |
dc.date.accessioned | 2021-06-17T07:03:51Z | - |
dc.date.available | 2024-08-27 | |
dc.date.copyright | 2019-08-27 | |
dc.date.issued | 2019 | |
dc.date.submitted | 2019-07-29 | |
dc.identifier.citation | [1]Riera Romo M, Perez-Martinez D, Castillo Ferrer C. Innate immunity in vertebrates: an overview. Immunology 2016;148(2):125-39.
[2]Shi C, Pamer EG. Monocyte recruitment during infection and inflammation. Nat Rev Immunol 2011;11(11):762-74. [3]Ruytinx P, Proost P, Van Damme J, Struyf S. Chemokine-Induced Macrophage Polarization in Inflammatory Conditions. Front Immunol 2018;9:1930. [4]Hussell T, Bell TJ. Alveolar macrophages: plasticity in a tissue-specific context. Nat Rev Immunol 2014;14(2):81-93. [5]van Kooyk Y, Rabinovich GA. Protein-glycan interactions in the control of innate and adaptive immune responses. Nat Immunol 2008;9(6):593-601. [6]Crocker PR, Paulson JC, Varki A. Siglecs and their roles in the immune system. Nat Rev Immunol 2007;7(4):255-66. [7]Macauley MS, Crocker PR, Paulson JC. Siglec-mediated regulation of immune cell function in disease. Nat Rev Immunol 2014;14(10):653-66. [8]Campbell KS, Purdy AK. Structure/function of human killer cell immunoglobulin-like receptors: lessons from polymorphisms, evolution, crystal structures and mutations. Immunology 2011;132(3):315-25. [9]Yamanaka M, Kato Y, Angata T, Narimatsu H. Deletion polymorphism of SIGLEC14 and its functional implications. Glycobiology 2009;19(8):841-6. [10]Ali SR, Fong JJ, Carlin AF, Busch TD, Linden R, Angata T, Areschoug T, Parast M, Varki N, Murray J and others. Siglec-5 and Siglec-14 are polymorphic paired receptors that modulate neutrophil and amnion signaling responses to group B Streptococcus. J Exp Med 2014;211(6):1231-42. [11]Angata T, Ishii T, Motegi T, Oka R, Taylor RE, Soto PC, Chang YC, Secundino I, Gao CX, Ohtsubo K and others. Loss of Siglec-14 reduces the risk of chronic obstructive pulmonary disease exacerbation. Cell Mol Life Sci 2013;70(17):3199-210. [12]Fong JJ, Sreedhara K, Deng L, Varki NM, Angata T, Liu Q, Nizet V, Varki A. Immunomodulatory activity of extracellular Hsp70 mediated via paired receptors Siglec-5 and Siglec-14. Embo j 2015;34(22):2775-88. [13]Chang YC, Uchiyama S, Varki A, Nizet V. Leukocyte inflammatory responses provoked by pneumococcal sialidase. MBio 2012;3(1). [14]Hayakawa T, Khedri Z, Schwarz F, Landig C, Liang SY, Yu H, Chen X, Fujito NT, Satta Y, Varki A and others. Coevolution of Siglec-11 and Siglec-16 via gene conversion in primates. BMC Evol Biol 2017;17(1):228. [15]Wang Y, Neumann H. Alleviation of neurotoxicity by microglial human Siglec-11. J Neurosci 2010;30(9):3482-8. [16]Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell 2010;140(6):805-20. [17]Ishida A, Akita K, Mori Y, Tanida S, Toda M, Inoue M, Nakada H. Negative regulation of Toll-like receptor-4 signaling through the binding of glycosylphosphatidylinositol-anchored glycoprotein, CD14, with the sialic acid-binding lectin, CD33. J Biol Chem 2014;289(36):25341-50. [18]Chen W, Han C, Xie B, Hu X, Yu Q, Shi L, Wang Q, Li D, Wang J, Zheng P and others. Induction of Siglec-G by RNA viruses inhibits the innate immune response by promoting RIG-I degradation. Cell 2013;152(3):467-78. [19]Chen GY, Brown NK, Wu W, Khedri Z, Yu H, Chen X, van de Vlekkert D, D'Azzo A, Zheng P, Liu Y. Broad and direct interaction between TLR and Siglec families of pattern recognition receptors and its regulation by Neu1. Elife 2014;3:e04066. [20]Singh RK, Dhama K, Karthik K, Khandia R, Munjal A, Khurana SK, Chakraborty S, Malik YS, Virmani N, Singh R and others. A Comprehensive Review on Equine Influenza Virus: Etiology, Epidemiology, Pathobiology, Advances in Developing Diagnostics, Vaccines, and Control Strategies. Front Microbiol 2018;9:1941. [21]Dou D, Revol R, Ostbye H, Wang H, Daniels R. Influenza A Virus Cell Entry, Replication, Virion Assembly and Movement. Front Immunol 2018;9:1581. [22]Taubenberger JK, Kash JC. Influenza virus evolution, host adaptation, and pandemic formation. Cell Host Microbe 2010;7(6):440-51. [23]Moghadami M. A Narrative Review of Influenza: A Seasonal and Pandemic Disease. Iran J Med Sci 2017;42(1):2-13. [24]Lai S, Qin Y, Cowling BJ, Ren X, Wardrop NA, Gilbert M, Tsang TK, Wu P, Feng L, Jiang H and others. Global epidemiology of avian influenza A H5N1 virus infection in humans, 1997-2015: a systematic review of individual case data. Lancet Infect Dis 2016;16(7):e108-e118. [25]Wang XY, Kilgore PE, Lim KA, Wang SM, Lee J, Deng W, Mo MQ, Nyambat B, Ma JC, Favorov MO and others. Influenza and bacterial pathogen coinfections in the 20th century. Interdiscip Perspect Infect Dis 2011;2011:146376. [26]Klemm C, Boergeling Y, Ludwig S, Ehrhardt C. Immunomodulatory Nonstructural Proteins of Influenza A Viruses. Trends Microbiol 2018;26(7):624-636. [27]Faisca P, Desmecht D. Sendai virus, the mouse parainfluenza type 1: a longstanding pathogen that remains up-to-date. Res Vet Sci 2007;82(1):115-25. [28]Kato A, Cortese-Grogan C, Moyer SA, Sugahara F, Sakaguchi T, Kubota T, Otsuki N, Kohase M, Tashiro M, Nagai Y. Characterization of the amino acid residues of sendai virus C protein that are critically involved in its interferon antagonism and RNA synthesis down-regulation. J Virol 2004;78(14):7443-54. [29]Nakanishi M, Otsu M. Development of Sendai virus vectors and their potential applications in gene therapy and regenerative medicine. Curr Gene Ther 2012;12(5):410-6. [30]Liu Q, Zhou YH, Yang ZQ. The cytokine storm of severe influenza and development of immunomodulatory therapy. Cell Mol Immunol 2016;13(1):3-10. [31]Haller O, Kochs G, Weber F. The interferon response circuit: induction and suppression by pathogenic viruses. Virology 2006;344(1):119-30. [32]Moreira-Teixeira L, Mayer-Barber K, Sher A, O'Garra A. Type I interferons in tuberculosis: Foe and occasionally friend. J Exp Med 2018;215(5):1273-1285. [33]Mayer-Barber KD, Andrade BB, Oland SD, Amaral EP, Barber DL, Gonzales J, Derrick SC, Shi R, Kumar NP, Wei W and others. Host-directed therapy of tuberculosis based on interleukin-1 and type I interferon crosstalk. Nature 2014;511(7507):99-103. [34]Meager A. Biological assays for interferons. J Immunol Methods 2002;261(1-2):21-36. [35]Huang PY, Guo JH, Hwang LH. Oncolytic Sindbis virus targets tumors defective in the interferon response and induces significant bystander antitumor immunity in vivo. Mol Ther 2012;20(2):298-305. [36]Ramos I, Fernandez-Sesma A. Modulating the Innate Immune Response to Influenza A Virus: Potential Therapeutic Use of Anti-Inflammatory Drugs. Front Immunol 2015;6:361. [37]Cargnello M, Roux PP. Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases. Microbiol Mol Biol Rev 2011;75(1):50-83. [38]Gaur P, Munjhal A, Lal SK. Influenza virus and cell signaling pathways. Med Sci Monit 2011;17(6):Ra148-54. [39]Heaton SM, Borg NA, Dixit VM. Ubiquitin in the activation and attenuation of innate antiviral immunity. J Exp Med 2016;213(1):1-13. [40]Orr SJ, Morgan NM, Buick RJ, Boyd CR, Elliott J, Burrows JF, Jefferies CA, Crocker PR, Johnston JA. SOCS3 targets Siglec 7 for proteasomal degradation and blocks Siglec 7-mediated responses. J Biol Chem 2007;282(6):3418-22. [41]Nutku E, Aizawa H, Hudson SA, Bochner BS. Ligation of Siglec-8: a selective mechanism for induction of human eosinophil apoptosis. Blood 2003;101(12):5014-20. [42]Atkin-Smith GK, Duan M, Chen W, Poon IKH. The induction and consequences of Influenza A virus-induced cell death. Cell Death Dis 2018;9(10):1002. [43]Zimmermann M, Meyer N. Annexin V/7-AAD staining in keratinocytes. Methods Mol Biol 2011;740:57-63. [44]Niles AL, Moravec RA, Riss TL. In vitro viability and cytotoxicity testing and same-well multi-parametric combinations for high throughput screening. Curr Chem Genomics 2009;3:33-41. [45]Kelly B, O'Neill LA. Metabolic reprogramming in macrophages and dendritic cells in innate immunity. Cell Res 2015;25(7):771-84. [46]Chang YC, Nizet V. The interplay between Siglecs and sialylated pathogens. Glycobiology 2014;24(9):818-25. [47]Sun S, Wang Q, Zhao F, Chen W, Li Z. Glycosylation site alteration in the evolution of influenza A (H1N1) viruses. PLoS One 2011;6(7):e22844. [48]Patel N, Brinkman-Van der Linden EC, Altmann SW, Gish K, Balasubramanian S, Timans JC, Peterson D, Bell MP, Bazan JF, Varki A and others. OB-BP1/Siglec-6. a leptin- and sialic acid-binding protein of the immunoglobulin superfamily. J Biol Chem 1999;274(32):22729-38. [49]Shahangian A, Chow EK, Tian X, Kang JR, Ghaffari A, Liu SY, Belperio JA, Cheng G, Deng JC. Type I IFNs mediate development of postinfluenza bacterial pneumonia in mice. J Clin Invest 2009;119(7):1910-20. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/72696 | - |
dc.description.abstract | Siglec為辨識唾液酸的受體,其中的Siglec-5和Siglec-14表現於單核球細胞、巨噬細胞和嗜中性白血球,能夠受相同的配體活化,分別傳遞抑制性和活化性的訊息。人類已知具有SIGLEC5/14基因多型性,此基因多型性可影響個體在病原體感染後的抗菌結果及發炎程度。我們與其他的實驗室均發現Siglec-14可以促進細胞在細菌感染後的促炎性反應,但關於SIGLEC14基因多型性在病毒感染後對個體的促炎性反應或是抗病毒反應之研究則尚不清楚。A型流感病毒之感染經常伴隨細胞激素風暴發生,造成肺部組織受損。仙台病毒能引起強烈的宿主抗病毒反應,被廣泛用來探討宿主IFNs和其下游基因表現,因此我們將同時以A型流感病毒與仙台病毒對人類細胞株的感染模型來探討SIGLEC5/14基因多型性對單核球細胞抗病毒的先天免疫反應之調控。我們發現表現Siglec-14的THP-1細胞(S14/THP-1)在H5N1或SeV感染時促炎性細胞激素產生較S5/THP-1細胞多,而且H5N1感染時,S14/THP-1細胞中的p38和AKT也較S5/THP-1細胞活化,顯示Siglec-14可能透過增加p38和AKT的活化來增進細胞的促炎性反應。IAV或SeV感染時,S5/THP-1細胞製造比S14/THP-1細胞多IFN-b的mRNA,但是IFN-b蛋白表現量不易測定,而且參與調控type I IFN表現的磷酸化態TBK1和IRF3也無法在H5N1感染後被偵測到,所以我們之後會再尋找適合的實驗方法或條件得到這個部分的結論。此外,我們發現Siglec-5和Siglec-14不會影響IAV複製,表示Siglec-5和Siglec-14對於先天免疫反應不同的調控與IAV進入細胞的多寡和新病毒顆粒產生的速度無關。已知鍵結具有ITIM的Siglecs會造成細胞凋亡,因此我們也進一步探討Siglec-5和Siglec-14是否會影響單核球細胞被病毒感染後的存亡。結果顯示S14/THP-1細胞在IAV感染時的存活率較S5/THP-1細胞好,但是其調控機制還不清楚。除此之外,我們的實驗結果也顯示IAV會直接結合Siglec-5和Siglec-14,暗指IAV可能可以透過鍵結Siglec-5和Siglec-14直接影響單核球細胞抗病毒的先天免疫反應。 | zh_TW |
dc.description.abstract | Siglecs (sialic acid-binding immunoglobulin-like lectins) are receptors recognizing sialic acids. Siglec-5 and Siglec-14, expressing on monocytes, macrophages and neutrophils, can transduce inhibitory and activating signals through ITIM and ITAM, respectively, upon ligand engagement. In addition, SIGLEC5/14 polymorphism has been discovered in human population and the presence of SIGLEC14 WT allele has been linked to exaggerated host antimicrobial and inflammatory responses upon infection. We and others have demonstrated that Siglec-14 promotes proinflammatory responses of macrophages and neutrophils upon bacterial infection. However, the role of SIGLEC5/14 polymorphism in host proinflammatory and antiviral responses upon viral infection is largely unknown. Influenza A virus (IAV) infection often associates with exacerbated host inflammation (cytokine storm) and eventually leads to lung tissue destruction. Sendai virus (SeV), structurally similar to IAV, is a wildly used model to study host antiviral responses since SeV infection constantly mounts a robust host interferon (IFN) response. Thus, we applied both IAV and SeV to infect THP-1 cells expressing either Siglec-5 or Siglec-14 to explore the role of SIGLEC5/14 polymorphism in antiviral innate immune responses. We found that H5N1 or SeV infection stimulates more TNF-a and IL-1b production in S14/THP-1 cells (THP-1 cells expressing Siglec-14) compared with that produced in infected S5/THP-1 cells (THP-1 cells expressing Siglec-5). In addition, H5N1 infection caused enhanced p38 and AKT phosphorylation in S14/THP-1 cells. Our data suggest that Siglec-14 may promote proinflammatory responses through activating p38 and AKT signaling pathway upon viral infection. In contrast, reduced production of IFN-b mRNA was observed in S14/THP-1 cells infected with IAV or SeV. Neither the released IFN protein nor the activated TBK1 and IRF3 can be detected in our experimental system, we will therefore optimize experimental conditions to further clarify the role of Siglec-14 in regulating host IFN responses. Comparable IAV replication was observed in S5/THP-1 and S14/THP-1 cells, indicating that reduced IFN responses in the S14/THP-1 cells upon IAV infection were not directly affected by restricted virus entry and virion production by Siglec-14. Engagement of ITIM-bearing Siglecs have been shown to trigger cell death in various cell types, we next examined whether Sigelc-5 and Siglec-14 can modulate cell survival upon IAV infection. Our data showed that IAV-infected S14/THP-1 cells survive better than infected S5/THP-1 cells, although the detail mechanism is still unknown. Finally, we demonstrated that IAV can directly interact with Siglec-5 and Siglec-14, indicating that IAV may engage Siglec-5 or Siglec-14 expressing on the monocytes to modulate their antiviral innate immune responses. | en |
dc.description.provenance | Made available in DSpace on 2021-06-17T07:03:51Z (GMT). No. of bitstreams: 1 ntu-108-R06445129-1.pdf: 2271495 bytes, checksum: a77feb623fa78474700a99841e804fcb (MD5) Previous issue date: 2019 | en |
dc.description.tableofcontents | 口試委員審定書 i
致謝 ii 中文摘要 iii Abstract v 目錄 vii 壹、 研究背景與動機 1 一、 先天免疫反應 1 二、 Sialic acid-binding immunoglobulin-like lectins (Siglecs) 2 1. Siglecs簡介 2 2. Siglec成對受體(paired receptors) 4 3. Siglecs與模式識別受體(pattern recognition receptors,PRRs)的交互作用 6 三、 流感病毒與仙台病毒 6 1.流感病毒 (Influenza virus) 6 2.仙台病毒 (Sendai virus,SeV) 9 四、 研究動機 10 貳、 實驗材料與研究方法 12 一、 實驗材料 12 1.病毒株 (Virus strain) 12 2.細胞株 (Cell line) 12 3.重組人類siglec-Fc嵌合蛋白 (Recombinant human siglec-Fc chimeric protein) 13 4.引子 (primer) 13 5.酵素免疫分析法試劑組 14 6.抗體 14 二、 研究方法 15 1.IAV的生產及定量 15 2.西方墨點法 (Western blot) 16 3.免疫沉澱試驗(Immunoprecipitation assay) 16 4.病毒感染細胞之細胞激素的mRNA表現量 17 5.病毒感染細胞之細胞激素的蛋白表現量 18 6.偵測細胞內病毒RNA表現量和培養液中病毒效價 19 7.病毒感染細胞之訊息傳遞蛋白的活化情形 20 8.病毒感染細胞之細胞存活率 21 參、 研究結果 23 一、 Siglec-14可促進單核球細胞於IAV和SeV感染時促炎性細胞激素的產生 23 二、 表現Siglec-14的單核球細胞於IAV和SeV感染時會減少第一型干擾素的產生 24 三、 表現Siglec-14可以增加單核球細胞在IAV感染時p38和AKT的活化 26 四、 Siglec-5和Siglec-14不會影響IAV複製過程 27 五、 IAV感染時S14/THP-1細胞的存活率較S5/THP-1細胞高 28 六、 IAV可以結合Sigec-5和Siglec-14 30 肆、 討論與未來研究方向 32 參考文獻 36 附錄 50 | |
dc.language.iso | zh-TW | |
dc.title | 探討Siglec-5和Siglec-14受體對於單核球細胞抗病毒反應的調控作用 | zh_TW |
dc.title | To investigate the roles of Siglec-5 and Siglec-14 in antiviral responses in monocytes | en |
dc.type | Thesis | |
dc.date.schoolyear | 107-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 楊宏志,劉旻禕 | |
dc.subject.keyword | Siglec,SIGLEC5/14基因多型性,先天免疫反應,病毒感染, | zh_TW |
dc.subject.keyword | Siglec,SIGLEC5/14 polymorphisms,innate immune responses,viral infection, | en |
dc.relation.page | 51 | |
dc.identifier.doi | 10.6342/NTU201902153 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2019-07-30 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 微生物學研究所 | zh_TW |
顯示於系所單位: | 微生物學科所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-108-1.pdf 目前未授權公開取用 | 2.22 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。